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Abstract
Background: The co-existence of two genetically distinct metabolic disorders in the same patient has rarely been 
reported. Phenylketonuria (PKU) is an inborn error of the metabolism resulting from a phenylalanine hydroxylase 
deficiency. Fabry disease (FD) is an X-linked lysosomal storage disorder due to a deficiency of the enzyme alpha-
galactosidase A.
Case presentation: We report a case of a 3 year- old boy affected by classic PKU and FD, both confirmed by molecular 
data. The FD was suspected at the age of 21 months on the presence of non-specific GI symptoms (severe abdominal 
pain and periodically appearance of not specific episodes of gastroenteritis) apparently non related to PKU.
Conclusion: This is the first report of co-existence of FD and PKU, two different congenital inborn of metabolism and in 
consideration of the prevalence of each disease this chance association is a very unusual event. The co-existence of 
this diseases made very difficult the correct interpretation of clinical symptoms as lack of appetite, severe abdominal 
pain and non-specific gastroenteritis episodes. Furthermore, this case report helps to define the early clinical 
phenotype of FD.
Background
The presence of two genetically distinct metabolic dis-
eases in the same patient has rarely reported. Phenylketo-
nuria (PKU) (OMIM 221600) is inborn error of the
metabolism resulting from a deficiency of phenylalanine
hydroxylase (PAH). The Phenylalanine (Phe) hydroxylase
gene is located on chromosome 12q22-q24.1 and so far
more than 400 different mutant Phe hydroxylase alleles
have been described[1]. A Phe restricted diet can
improve the effects of high serum Phe on cognitive func-
tions. Fabry disease (FD) (OMIM 301500) is an X-linked
lysosomal storage disorder due to a deficiency of the
enzyme alpha-galactosidase A (GLA). The GLA gene
maps at Xq22.1 and more than 400 mutations have been
recorded in the Human Gene Mutation Database [2]. The
disease affects kidney, myocardium, central nervous sys-
tem, heart, ears, eyes, skin and, in many patients, the gas-
trointestinal tract (GI) [3]. FD can become clinically
manifest in childhood with chronic neuropathic pain,
hypohidrosis/hyperhidrosis, angiokeratoma, acroparaes-
thesiae, non-specific GI symptoms and hearing problems
[4]. Recently, recombinant enzyme replacement therapy
(ERT) has become available. The diagnosis of FD is often
delayed in the pediatric population. The symptoms may
appear in a nonspecific pattern in this age group, and
often many years are required to identify the underlying
nature of the complaints. Pedigree studies and a careful
family history are important and in the absence of such
information, the diagnosis of FD, confirmed by enzyme/
genetic analysis, is usually suspected on the basis of
strong clinical signs and recognition of the peculiarity of
the clinical findings [5]. We report a new pediatric case of
FD with early GI involvement in a 3- year-old boy
affected by PKU.
Case presentation
A 3 -year-old boy was first seen in our department at the
age of 20 days for a positive neonatal screening for PKU.
He was born at 41 weeks of gestation to non-consanguin-
eous parents, with a birth weight of 2810 g (10th centile).
Family history was unremarkable for FD except for a
maternal uncle deceased at the age of 53 years of cerebral
stroke, and a grandmother suffers of systemic hyperten-
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Page 2 of 3sion. A maternal niece has developed severe renal failure
at birth and underwent to renal transplantation at the age
of 19 years for polycystic kidneys (Fig. 1). In our child an
hyperphenylalaninemia due to BH4-deficiency was
excluded by BH4 loading test (20 mg/Kg), analysis of uri-
nary pterins, and determination of dihydropterine
reductase activity on blood spot. Moreover, mutation
analysis by restriction enzyme analysis was used to iden-
tify his genotype resulting homozygous for c.143 T>C
mutation on exon 2 that changes in the protein Lys with
Ser (p.L48S). The patient was subjected to a low-Phe diet
and supplementation with Phe-free amino-acid mixtures.
Treatment compliance was excellent with a mean of
serum Phe value ~3 mg/dl during the day and good toler-
ance (440 mg Phe/day). Growth, neurological and psy-
chological development were normal. At the age of 28
months, the boy began to show a slow growth, lack of
appetite, severe abdominal pain and appearance often of
episodes of gastroenteritis, resolving spontaneously and
not related with the diet treatment. Laboratory routine
investigations, sweat test, acid-base status, inflammatory
parameters, stool culture, oven and parassite, faecal
occult blood test, antigliadin antibodies (AGA), antien-
domisium antibodies (EMA), tissue transglutaminase
(tTG), were in the normal range. Symptoms of non spe-
cific enteropathy, such recurrent diffuse abdominal pain
and diarrhea continued and at the age of 36 months he
showed a deceleration of linear growth velocity (from 50th
centile to 10-25th centile) although the BMI was in normal
range. These symptoms combined with the familiar his-
tory, suggested us a possible FD. At clinical examination
no angiokeratomas were found.
The diagnosis was confirmed by the reduced plasma a-
galactosidase A (0,32 nmol/h/ml), decreased activity
assayed in leucocytes [0,65 nmol/mg.prot/h (normal
range: 26-80)] and the molecular analysis of GLA gene
documented the hemizygous missense mutation
g.5234G>A 2 in the exon 2 that changes in the protein
Arg with Hys (p.R112H). In the mother, the mutation
analysis showed that she carries the same heterozygous
mutation. We performed a systematic pedigree analysis
by the assay of GAL activity in the family and mutation
analysis to brothers, sisters, nephews of the mother that
resulted normal. The grandmother (II.2) and a brother
(III.1) of the mother refused to undergo to molecular
analysis (Fig. 1).
Due to the lack of other clinical signs we decided not to
start ERT but to perform a clinical follow-up every 6
months. Today the patient is 5-year-old, continues a diet
therapy for PKU and severe abdominal pain is present
periodically without triggering factors in absence of other
symptoms.
Conclusion
The clinical relevance of this case is the combination of
two different metabolic inherited diseases and the early
presentation of FD. The co-existence of PKU and FD
made very difficult the correct interpretation of clinical
symptoms as lack of appetite, severe abdominal pain and
non-specific gastroenteritis episodes. In fact GI symp-
toms and feeding problems also in young PKU children
are present [6]. Non specific enteropathy has been
reported in about 80% of pediatric FD patients4 and these
symptoms must alert pediatricians to possible FD, also
because the incidence of the disease seems higher than
previously estimated [7]. It is, therefore, difficult predict-
ing the clinical outcome in this young patient who is still
free of organ involvement. The mutation p.R112 H found
in our patient has been previously identified in patients
with either the classic phenotype or the cardiac-variant
phenotype [8]. Given that the reversibility of disease pro-
gression in adulthood is limited, early ERT appears rea-
sonable, because the disease progresses with age.
However, the optimum time to start ERT in order to pre-
vent end-stage organ damage is also unknown. It is possi-
ble that beginning of therapy at an early age, before the
occurrence of significant organ damage and dysfunction,
produces better clinical results. Moreover, little is known
about the natural history of the disease in childhood, and
systematic prospective data on the clinical manifestations
of FD by ERT in the pediatric population are not avail-
able. It is essential, however, to study the therapeutic and
possibly preventive effects of this treatment approach on
children in a controlled way. Clinical trials are currently
underway to evaluate the safety and efficacy of enzyme
replacement therapy in children with FD [9]. According
to current expert recommendations, ERT in male
patients should ideally be provided in the second decade
of life or as soon as clinical signs and symptoms, such as
left ventricular hypertrophy, proteinuria, hypoidrosis or
pain, are observed [8]. Further, based on our knowledge,
cases of FD and PKU have been never described in the





II.3 cerebral stroke at the age of 53 years 
III.1 untested 
III. 2, 3, 4, 5. normal at genetic analysis 
III. 6, 7 non-affected at enzymatic analysis 
IV. 1 renal transplant 
IV. 3, 5, 7, 8, 9, 10 non-affected 
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Page 3 of 3look for the coexistence of other inherited metabolic dis-
eases when the clinical history is not completely consis-
tent with the well assessed first diagnosis.
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